Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Long-Term Deferred Tax (2018 - 2020)

Historic Long-Term Deferred Tax for Ernexa Therapeutics (ERNA) over the last 3 years, with Q4 2020 value amounting to $34000.0.

  • Ernexa Therapeutics' Long-Term Deferred Tax rose 8888.89% to $34000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $34000.0, marking a year-over-year increase of 8888.89%. This contributed to the annual value of $34000.0 for FY2020, which is 8888.89% up from last year.
  • Ernexa Therapeutics' Long-Term Deferred Tax amounted to $34000.0 in Q4 2020, which was up 8888.89% from $18000.0 recorded in Q4 2019.
  • Ernexa Therapeutics' Long-Term Deferred Tax's 5-year high stood at $34000.0 during Q4 2020, with a 5-year trough of $18000.0 in Q4 2019.
  • Over the past 3 years, Ernexa Therapeutics' median Long-Term Deferred Tax value was $23000.0 (recorded in 2018), while the average stood at $25000.0.
  • As far as peak fluctuations go, Ernexa Therapeutics' Long-Term Deferred Tax tumbled by 2173.91% in 2019, and later surged by 8888.89% in 2020.
  • Quarter analysis of 3 years shows Ernexa Therapeutics' Long-Term Deferred Tax stood at $23000.0 in 2018, then fell by 21.74% to $18000.0 in 2019, then soared by 88.89% to $34000.0 in 2020.
  • Its Long-Term Deferred Tax stands at $34000.0 for Q4 2020, versus $18000.0 for Q4 2019 and $23000.0 for Q4 2018.